2024
Barriers to and facilitators of improving physical activity and nutrition behaviors during chemotherapy for breast cancer: a sequential mixed methods study
Puklin L, Irwin M, Sanft T, Ferrucci L, Harrigan M, McGowan C, Cartmel B, Zupa M, Winer E, Deyling M, Ligibel J, Basen-Engquist K, Spiegelman D, Sharifi M. Barriers to and facilitators of improving physical activity and nutrition behaviors during chemotherapy for breast cancer: a sequential mixed methods study. Supportive Care In Cancer 2024, 32: 590. PMID: 39141176, DOI: 10.1007/s00520-024-08789-5.Peer-Reviewed Original ResearchConceptsPhysical activityLifestyle interventionSelf-reported PA questionnaireSelf-reported diet qualityBreast cancerHealthy Eating Index-2015Stage I-III breast cancerBenefits of PASequential mixed methods studyI-III breast cancerChemotherapy-related symptomsMixed methods studyThematic content analysisBehavioral goalsSense of controlBody mass indexPA questionnaireSemi-structured interviewsMean body mass indexTranscribed verbatimIntervention armTailored educationDiet qualityNutritional behaviorMental benefitsImproving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial
Puklin L, Ferrucci L, Harrigan M, McGowan C, Zupa M, Cartmel B, Li F, Ligibel J, Spiegelman D, Sharifi M, Sanft T, Irwin M. Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial. Cancer 2024, 130: 2440-2452. PMID: 38470431, PMCID: PMC11214600, DOI: 10.1002/cncr.35280.Peer-Reviewed Original ResearchPhysical activityDiet qualityHEI-2015Strength trainingLifestyle behaviorsHealthy Eating Index (HEI)-2015Breast cancerAssociated with baseline fatigueImprove physical activityImprove lifestyle behaviorsHigher HEI-2015Associated with higher oddsExercise interventionUsual careIntervention armIntervention groupBaseline fatigueLifestyle interventionYearlong interventionLower fatigueHigher oddsSecondary analysisLogistic regressionNewly diagnosed patientsStudy arms
2022
Factors associated with sleep health in young women after breast cancer treatment
Hwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. Factors associated with sleep health in young women after breast cancer treatment. Research In Nursing & Health 2022, 45: 680-692. PMID: 36102624, DOI: 10.1002/nur.22264.Peer-Reviewed Original ResearchConceptsPoor sleep healthSleep healthCognitive appraisalPittsburgh Sleep Quality IndexWorse family functioningBreast cancerPsychological symptom distressYoung womenContext of familyFamily functioningDiverse cancer survivorsRoutine survivorship carePsychosocial variablesCross-sectional designMediation effectSleep Quality IndexSleep health disparitiesBreast cancer treatmentSignificant clinical problemPsychosocial factorsNon-Hispanic whitesHalf of participantsSurvivorship careCancer survivorsMean ageRandomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.
Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.Peer-Reviewed Original ResearchRelative dose intensityHigh relative dose intensityBreast cancerDose-response effectPhysical activityPA interventionsNeoadjuvant chemotherapyChemotherapy completionDiet qualityStage I breast cancerEndocrine therapy adherenceTrial of dietDifferent chemotherapy regimensI breast cancerBody mass indexPatient-reported outcomesHealthy Eating IndexBetter diet qualityHigh physical activityMore physical activityElectronic medical recordsChi-square testUC participantsChemotherapy regimensSecondary endpoints0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment
Hwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment. Sleep 2022, 45: a259-a260. DOI: 10.1093/sleep/zsac079.587.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexPoor sleep healthSleep healthBreast cancerPsychosocial dataGlobal Pittsburgh Sleep Quality IndexYoung womenCancer treatmentRoutine survivorship careSevere night sweatsSleep Quality IndexBreast cancer treatmentCross-sectional studyPrimary cancer treatmentSignificant clinical problemYears of ageQuality of lifeNon-Hispanic whitesWarrants further investigationEndocrine therapyGeneral Functioning subscaleNight sweatsSurvivorship careClinical factorsCancer survivors
2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy
2020
Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Onishi N, Li W, Newitt D, Harnish R, Gibbs J, Jones E, Nguyen A, Wilmes L, Joe B, Campbell M, Basu A, van’t Veer L, DiMichele A, Yee D, Berry D, Albain K, Boughey J, Chien A, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, Asare S, Yau J, Yau C, Esserman L, Hylton N. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer. Cancer Research 2020, 80: pd9-05-pd9-05. DOI: 10.1158/1538-7445.sabcs19-pd9-05.Peer-Reviewed Original ResearchPathological complete responseBackground parenchymal enhancementInferior treatment responseHormone receptor-positive breast cancerPathologic complete response rateReceptor-positive breast cancerPositive breast cancerTreatment responseHR cohortBreast cancerBreast MRINeoadjuvant chemotherapyNon-pCRDegree of BPEI-SPY 2 TRIALQuantitative background parenchymal enhancementStage II/III breast cancerContralateral breast parenchymaPost-NAC MRIHormone receptor statusHR+ breast cancerEffects of chemotherapyEnhanced suppressionStatistically significant associationHR+ cancersAbstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu M, Robinson P, Yau C, Wallace A, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain K, Boughey J, Han H, Elias A, Kalinsky K, Clark A, Kemmer K, Isaacs C, Lang J, Lu J, Sanft T, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Haugen P, Wilson A, Singhrao R, Asare S, Sanil A, Berry D, Esserman L. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2020, 80: p3-09-02-p3-09-02. DOI: 10.1158/1538-7445.sabcs19-p3-09-02.Peer-Reviewed Original ResearchPathological complete responseHER2 negative breast cancerI-SPY 2 TRIALWeeks of paclitaxelNegative breast cancerNeoadjuvant therapyBreast cancerHR-/HER2High-risk stage II/III breast cancerImmune-related adverse eventsPathologic complete response rateRandomized phase 2 trialStage II/III breast cancerHormone-receptorI-SPYEvaluate novel agentsGrade 3 colitisGrade 3 pneumonitisGrade 3 transaminitisPhase 2 trialPhase 3 trialBayesian predictive probability of successNeoadjuvant trialsWeekly paclitaxelComplete response